<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew S Davenport, MD, FSAR, FSCBTMR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey H Newhouse, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Herbert Y Kressel, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 19, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3479013415"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Health care providers who refer patients for computed tomography (CT) must consider whether to request intravenous and/or enteric (oral or rectal) contrast administration as part of the exam. While contrast administration with CT is often necessary to obtain the diagnosis, there are small risks for an acute adverse reaction or contrast-induced nephropathy (CIN).</p><p>Standards for patient preparation and indications for contrast vary among radiology practices. However, guiding principles are presented here. Patient evaluation for oral and intravenous contrast administration prior to CT is described in this topic. Guidelines on the appropriate indications for contrast use and procedures for patient preparation before the CT exam are presented. </p><p>Related UpToDate content discusses: </p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenesis, diagnosis, and treatment of acute allergic-like reactions to iodinated contrast (see  <a class="medical medical_review" href="/z/d/html/2075.html" rel="external">"Diagnosis and treatment of an acute reaction to a radiologic contrast agent"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergy evaluation and indications for referral in patients with past moderate-to-severe allergic-like reactions to iodinated contrast (see  <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">"Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenesis and diagnosis of CIN (see  <a class="medical medical_review" href="/z/d/html/7241.html" rel="external">"Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of patients at risk of induced nephropathy (see  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography"</a>)</p><p></p><p class="headingAnchor" id="H2808967050"><span class="h1">TYPES OF CONTRAST MATERIAL</span></p><p class="headingAnchor" id="H621119267"><span class="h2">Types of intravenous contrast</span><span class="headingEndMark"> — </span>All modern clinical intravenous contrast injected for CT is iodine-based. A list of intravenous contrast agents used in CT can be found <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acr.org%2F-%2Fmedia%2FACR%2FFiles%2FClinical-Resources%2FContrast_Media.pdf&amp;token=IQxLzDq4doJGUgaZgeIY01IKkxx3ydwNAD3trB6%2B2YV9VFCAnyLrNLHtmmp2EYMjzDheSEca6wwFKrqbXQpAQN3StB3oZduNC2r1%2B4NcHFs%3D&amp;TOPIC_ID=113083" target="_blank">here</a> [<a href="#rid1">1</a>].</p><p>In patients with a history of an acute adverse event with iodinated contrast, providers should try to determine the type of agent that caused the reaction because this affects patient counseling and CT planning. Intravascular iodinated contrast is also given in other fluoroscopic exams such as angiography and intravenous urography, so adverse events related to these exams also may be relevant. A history of reaction to intravenous contrast given for magnetic resonance imaging (MRI) is <strong>not</strong> relevant because MRI contrast and CT contrast are not molecularly similar and are not cross-reactive. No cross-reactivity between iodinated and gadolinium-based contrast media has been observed. </p><p>Providers need not specify a particular type of intravenous contrast material when ordering a CT examination; this is usually determined by the hospital or the practice formulary. For CT, there are no important differences among the modern agents with regard to safety or efficacy.</p><p>Iodinated contrast agents are classified as low-osmolality contrast media (LOCM), iso-osmolality contrast media (IOCM), or high-osmolality contrast media (HOCM). For intravascular use, LOCM and IOCM are in use; HOCM is no longer used. Many iodinated contrast agents have been designed and marketed but all are soluble derivatives of a tri-iodinated benzene ring. Low-, iso-, and high-osmolality contrast are approximately 600 mOsm/kg H<sub>2</sub>O, approximately 300 mOsm/kg H<sub>2</sub>O, and 1200 mOsm/kg H<sub>2</sub>O, respectively. A list of intravenous contrast agents used in CT can be found in Appendix A of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acr.org%2F-%2Fmedia%2FACR%2FFiles%2FClinical-Resources%2FContrast_Media.pdf&amp;token=IQxLzDq4doJGUgaZgeIY01IKkxx3ydwNAD3trB6%2B2YV9VFCAnyLrNLHtmmp2EYMjzDheSEca6wwFKrqbXQpAQN3StB3oZduNC2r1%2B4NcHFs%3D&amp;TOPIC_ID=113083" target="_blank">2020 American College of Radiology Manual of Contrast Media</a> [<a href="#rid1">1</a>]. </p><p>HOCM are primarily of historical interest and are no longer used for intravascular administration due to a higher adverse event rate. LOCM and IOCM are considered equivalent with respect to the risk of contrast-induced nephropathy (CIN) at CT. </p><p class="headingAnchor" id="H963766525"><span class="h2">Types of oral or rectal contrast</span><span class="headingEndMark"> — </span>Some enteric (oral or rectal) contrast is iodine-based. All enteric contrast has the small potential to elicit an acute reaction. A list of contrast agents used in gastrointestinal CT examinations can be found in Appendix A of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acr.org%2F-%2Fmedia%2FACR%2FFiles%2FClinical-Resources%2FContrast_Media.pdf&amp;token=IQxLzDq4doJGUgaZgeIY01IKkxx3ydwNAD3trB6%2B2YV9VFCAnyLrNLHtmmp2EYMjzDheSEca6wwFKrqbXQpAQN3StB3oZduNC2r1%2B4NcHFs%3D&amp;TOPIC_ID=113083" target="_blank">2020 American College of Radiology Manual of Contrast Media</a> [<a href="#rid1">1</a>]. </p><p>The choice of enteric contrast is made by the radiologist primarily based on the exam indication and on any prior history of acute reaction.</p><p>Enteric contrast can be positive or negative. Positive enteric contrast (ie, high attenuation on CT), consisting of a dilute suspension of <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> sulfate or a dilute solution of an iodinated agent, is used for most indications. Negative enteric contrast (ie, water attenuation on CT) is used to delineate the bowel mucosa and improve detection of active inflammation [<a href="#rid2">2,3</a>] or active gastrointestinal bleeding [<a href="#rid4">4</a>]. Examples of negative contrast agents include very dilute solutions of barium, <a class="drug drug_general" data-topicid="10153" href="/z/d/drug information/10153.html" rel="external">methylcellulose</a>, and polyethylene glycol. Plain water can be used as a negative contrast material to distend the stomach and duodenum, but it does not distend the remainder of the bowel due to absorption. </p><p class="headingAnchor" id="H338202460"><span class="h1">DECIDING TO USE CONTRAST</span><span class="headingEndMark"> — </span>Appropriate contrast utilization is necessary to obtain acceptable diagnostic accuracy. Omitting contrast when it is indicated, or giving it when it is not, can lead to diagnostic and treatment errors, and unnecessary morbidity and cost. Added or repeated tests, delayed diagnoses, and accumulated patient radiation exposure are all potential adverse effects of an imaging exam performed suboptimally.</p><p>Both the ordering provider and the radiologist share the clinical and legal responsibility for each patient undergoing an imaging exam. However, most third-party payers require that contrast administration be specified when<strong><em> </em></strong>the<strong><em> </em></strong>exam is ordered for their precertification process, thereby placing the provider in the position of having to make the initial choice. This decision should be made after mutual consideration of the risks and benefits. In cases in which the choice is not obvious, a dialogue between the ordering provider and the radiologist can be helpful. </p><p class="headingAnchor" id="H2788385577"><span class="h2">Indications by type of study</span><span class="headingEndMark"> — </span>Whether enteric (oral or rectal) or intravenous contrast should be administered varies with the clinical indications for the CT exam. The American College of Radiology's (ACR) appropriateness criteria provide consensus guidelines on the choice of imaging modality and contrast material for many clinical situations [<a href="#rid1">1</a>]. In addition, UpToDate topics that recommend CT for patient management may specify whether oral and/or intravenous contrast is required, preferred, or not necessary for best diagnostic performance.</p><p class="headingAnchor" id="H1941870694"><span class="h3">Intravenous contrast</span><span class="headingEndMark"> — </span>For the most common CT exams, general guidelines for intravenous contrast are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Head CT</strong> – Intravenous contrast is not necessary for head trauma, acute stroke, or intracranial hemorrhage. Contrast is indicated for neoplasm, meningitis, encephalitis, focal neurologic deficits, skull base disorders, orbital and vision disorders, pituitary imaging, complicated sinonasal disease, seizures, and CT angiography [<a href="#rid5">5-8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervical CT –</strong> Intravenous contrast is not necessary for trauma unless arterial injury is a possibility or the mechanism of injury is penetrating. Contrast is indicated for a cervical mass or lymphadenopathy, suspected tumor or infection, abnormalities of cranial nerves X, XI, and XII, and brachial plexopathy [<a href="#rid9">9,10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiothoracic CT</strong> – Intravenous contrast material is not necessary for coronary calcium scoring, pulmonary parenchymal evaluation (eg, high-resolution chest CT for interstitial lung disease), or lymph node evaluation (eg, lymphoma). Contrast is indicated for CT of the heart and thoracic vessels, trauma, and for staging primary thoracic neoplasms [<a href="#rid11">11-15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominopelvic CT</strong> – Intravenous contrast material is not necessary for CT colonography, renal stone evaluation, and extraparenchymal lymphoma. Contrast is indicated for virtually all other gastrointestinal, hepatopancreaticobiliary, genitourinary, and gynecologic indications [<a href="#rid16">16-18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal CT</strong> – Intravenous contrast is not necessary for most CT exams of the extremities and spine. Contrast is indicated for evaluation of soft tissue masses and suspected septic arthritis or infected prostheses [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT angiography</strong> – Intravenous contrast is not necessary for monitoring a known aneurysm for growth or for detection of a hematoma. Contrast is indicated for evaluating the lumen of an artery, vein, or a pseudoaneurysm, and to assess for end-organ ischemia outside the brain or lung. It is also necessary to detect active bleeding [<a href="#rid4">4,21-23</a>]. </p><p></p><p class="headingAnchor" id="H2772498281"><span class="h3">Oral and rectal contrast</span><span class="headingEndMark"> — </span>Oral contrast is necessary to evaluate for gastric or small bowel perforation following penetrating trauma or surgery and may help to separate bowel loops in thin patients with minimal visceral fat (ie, body mass index &lt;25 kg/m<sup>2</sup>). Because it distends the stomach and intestinal tract, it improves delineation of the bowel from the mesentery and other peritoneal content (eg, hematoma, ascites, tumor nodules, etc) [<a href="#rid24">24,25</a>]. However, oral contrast has been shown to be unnecessary for accurate diagnosis of appendicitis and diverticulitis [<a href="#rid25">25-27</a>]. Oral contrast is not indicated for evaluation of the liver, kidneys, collecting systems, bladder, spleen, adrenal glands, retroperitoneum, bones, or vasculature. Negative enteric contrast can be helpful in the detection of occult gastrointestinal bleeding when paired with multiphasic CT angiography.</p><p>Rectal contrast is indicated for the detection of rectal or distal colonic leak. For most other indications, it is unnecessary.</p><p>There are relative but not absolute contraindications to oral contrast administration. In patients who are at risk of aspiration, it should be withheld or given judiciously, since aspirated oral contrast can cause pneumonitis [<a href="#rid28">28</a>]. Thus, oral contrast is potentially harmful and unnecessary to evaluate patients with suspected high-grade bowel obstruction [<a href="#rid29">29</a>]. The risk of aspiration may be highest with hypertonic oral contrast media compared with lower osmolality or barium-based solutions, but this has not been rigorously tested.</p><p>Oral contrast administration for CT in the emergency department has been associated with a 45- to 60-minute delay in disposition, which has led some practices to eliminate it for many indications in this practice setting [<a href="#rid25">25</a>].</p><p>In patients who have or are at risk for bowel perforation or a leak from a surgical anastomosis, barium-based oral contrast should be avoided. Extraluminal <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> is thought to increase the risk for mediastinitis or peritonitis, although the evidence supporting this principle is incomplete and involves old agents [<a href="#rid30">30-32</a>]. Patients with chronic leaks or fistulae are unlikely to be at risk for complications from barium-based oral contrast since<strong><em> </em></strong>these are cavities with chronic exposure to bowel content.</p><p class="headingAnchor" id="H3235654883"><span class="h1">PATIENTS WITH PAST REACTIONS TO CONTRAST</span><span class="headingEndMark"> — </span>Acute adverse reactions to contrast may occur after oral, intracavitary, or intravascular administration. For any history of an acute reaction to contrast, the provider should verify that the reaction was to an iodinated contrast (used for CT, radiography, fluoroscopy, or angiography) rather than to a noniodinated contrast agent used for other imaging modalities (eg, gadolinium used for magnetic resonance imaging [MRI]). The clinical details of the index reaction such as symptoms, their duration, and required therapy should also be obtained. </p><p>Prophylactic measures are unnecessary in patients who have hypersensitivity to other allergens unrelated to iodinated contrast, including gadolinium contrast used in MRI. The risk of an immediate hypersensitivity reaction to contrast material in patients with atopic risk factors (eg, allergies to unrelated substances or asthma) is approximately twice that of the general population [<a href="#rid33">33</a>]. However, shellfish allergy is not a specific risk factor for contrast reactions [<a href="#rid34">34</a>]. Shellfish allergies are to tropomyosin (a muscle protein), not iodine [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1172149799"><span class="h2">Evaluation of the index reaction</span><span class="headingEndMark"> — </span>Information should be gathered about the index reaction, including implicated contrast agent, clinical features, timing of onset, and severity. </p><p class="headingAnchor" id="H2421513806"><span class="h3">Culprit agent</span><span class="headingEndMark"> — </span>The incidence of an acute adverse reaction was more than 10-fold higher with intravenous administration of high-osmolality contrast media (HOCM) than with low-osmolality contrast media (LOCM) or iso-osmolality contrast media (IOCM) [<a href="#rid36">36</a>]. If the index reaction occurred before 1995, the agent was likely HOCM because LOCM was not yet available. If the prior acute reaction was to HOCM, the patient should be informed it is less likely to recur since LOCM or IOCM are now universally used for intravenous administration. However, despite the lower incidence of acute adverse reactions with LOCM and IOCM, possible cross-reactivity is presumed to exist between all iodinated contrast, regardless of osmolality. </p><p class="headingAnchor" id="H1926377083"><span class="h3">Acuity of past reaction</span><span class="headingEndMark"> — </span>Contrast reactions are categorized as immediate (also called acute) or nonimmediate (also called delayed). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate:</strong> Immediate reactions occur within minutes to one hour of exposure and are the primary concern when evaluating patients for future contrast administration. In the general population, with modern intravenous LOCM or IOCM, the observed rate of an immediate adverse reaction is approximately 0.6 percent of patients; the rate of severe adverse reactions is approximately 4 in 10,000, and death occurs in less than 1 in 170,000 patients [<a href="#rid33">33,37</a>]. </p><p></p><p class="bulletIndent1">Immediate adverse reactions with oral and intracavitary contrast occur but are less common than the immediate adverse reactions to intravascular contrast. The rates and manifestations of reactions to enteric contrast have not been well-studied. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed:</strong> Nonimmediate or delayed reactions occur more than one hour (usually &gt;6 hours) after contrast administration and can occur several days later [<a href="#rid38">38</a>]. The most common forms are maculopapular exanthema or delayed-onset urticaria. Maculopapular exanthema are usually mild and transient and are believed to be T cell-mediated in most cases [<a href="#rid39">39</a>]. Rare desquamative reactions have been reported. A delayed reaction may or may not recur, and premedication is usually not used in these patients because it has not been shown to prevent recurrence. Delayed contrast reactions are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/121742.html" rel="external">"Radiocontrast hypersensitivity: Nonimmediate (delayed) reactions"</a>.)</p><p></p><p class="headingAnchor" id="H3960895748"><span class="h3">Clinical features of immediate reactions</span><span class="headingEndMark"> — </span>For patients reporting a past immediate reaction, the clinical features of the index reaction should be reviewed in detail. Immediate reactions are further classified based on the underlying physiology (allergic-like or physiologic) and severity (mild, moderate, or severe) [<a href="#rid1">1</a>]. This classification predicts the likelihood and probable severity of a recurrent reaction, and determines the need for premedication prophylaxis (<a class="graphic graphic_algorithm graphicRef113232" href="/z/d/graphic/113232.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H218789361"><span class="h4">Allergic-like (hypersensitivity) reactions</span><span class="headingEndMark"> — </span>Allergic-like reactions are idiosyncratic, are not related to dose, may occur in patients without any history of prior exposure, and do not predictably recur after each contrast exposure. </p><p>Symptoms and signs of allergic-like reactions include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus, urticaria or angioedema</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal congestion, sneezing, conjunctivitis, rhinorrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Widespread erythema</p><p class="bulletIndent1"><span class="glyph">●</span>Hoarseness or stridor, itchy/scratchy throat, with or without hypoxia (ie, upper airway compromise)</p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive cough, wheezing, or chest tightness, with or without hypoxia (ie, lower airway compromise due to bronchoconstriction)</p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylactic shock (ie, hypotension and tachycardia)</p><p></p><p>Clinical manifestations of allergic-like reactions are identical to those<strong><em> </em></strong>of immediate hypersensitivity reactions to other drugs. In the past when these reactions were mostly caused by HOCM, the underlying mechanism was usually not immunoglobulin E (IgE)-mediated [<a href="#rid40">40,41</a>]. However, some severe immediate hypersensitivity reactions to LOCM and IOCM may be IgE-mediated, and allergy evaluations are being performed more commonly for patients with past severe immediate reactions. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">"Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media", section on 'Immediate reactions'</a>.)</p><p>Prevention of recurrent reactions is discussed below. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H2388986727"><span class="h4">Physiologic reactions</span><span class="headingEndMark"> — </span>Physiologic (also called toxic) reactions are dose-dependent and not mitigated by corticosteroid prophylaxis. They are concentration-dependent and likely related to direct chemotoxicity, osmotoxicity, or binding of endogenous molecules [<a href="#rid42">42-44</a>]. Symptoms and signs of physiologic reactions include: </p><p class="bulletIndent1"><span class="glyph">●</span>Transient flushing, warmth or chills</p><p class="bulletIndent1"><span class="glyph">●</span>Headache, dizziness, anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea/vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Metallic taste</p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Convulsions, seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Vasovagal reaction (ie, hypotension and bradycardia)</p><p></p><p>Reactions characterized by both allergic-like and physiologic manifestations should be classified as allergic-like. If classification is unclear, an allergic-like reaction should be assumed [<a href="#rid1">1</a>]. Prevention of recurrent physiologic reactions is discussed below. (See <a class="local">'Preventing recurrent physiologic reactions'</a> below.)</p><p>Cardiopulmonary arrest and pulmonary edema can be nonspecific endpoints of either a severe allergic-like or physiologic reaction [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H1648712739"><span class="h4">Severity</span><span class="headingEndMark"> — </span>Immediate reactions to iodinated contrast are classified as mild, moderate, or severe based on the nature of symptoms, their duration, and requirement for therapy.</p><p>Reactions are classified by severity as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – Reaction is self-limited, does not progress, and rarely requires treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate</strong> – Reaction usually requires treatment and may progress to a severe reaction if untreated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> – Reaction is life-threatening and can cause significant morbidity. Nearly all life-threatening contrast reactions occur within the first 20 minutes after contrast medium injection [<a href="#rid1">1</a>]. </p><p></p><p>In patients who have had a reaction, any subsequent reaction is likely to be of the same severity [<a href="#rid45">45,46</a>]. If repeat contrast administration is planned, medical staff with expertise to treat the anticipated symptoms should be readily available.</p><p class="headingAnchor" id="H2109935775"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>When referring patients with a prior moderate or severe immediate reaction for contrast-enhanced CT, consultation with the radiology service that will be performing the exam is advised. Whether or not the imaging could be modified to avoid contrast and whether or not premedication prophylaxis is appropriate should be discussed. These choices are highly individualized since the potential risks of a recurrent reaction should be weighed against the potential benefits of achieving an accurate diagnosis. The exam indication, available alternatives for diagnostic testing, and patient preferences should all be considered in the decision making (<a class="graphic graphic_algorithm graphicRef113232" href="/z/d/graphic/113232.html" rel="external">algorithm 1</a>).</p><p>If contrast administration is planned, preparations should be made to perform the exam in a setting where medical expertise is available to treat a reaction. </p><p class="headingAnchor" id="H3318755323"><span class="h3">Preventing recurrent allergic-like reactions</span><span class="headingEndMark"> — </span>Patients who have had a prior allergic-like reaction or unknown-type of reaction to contrast have an approximately fivefold increased risk of developing a future allergic-like reaction if exposed to the same class of contrast medium again [<a href="#rid42">42</a>]. Patients with multiple severe allergies or asthma are at greater risk as well, although probably not to the same extent [<a href="#rid1">1</a>].</p><p>The approach to prevention of subsequent reactions depends on the severity of the previous reaction. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe allergic-like </strong>– Future use of contrast should be avoided altogether when possible because recurrent reactions can occur despite changing contrast agents and premedication, and retrospective studies suggest that patients with past severe reactions are at risk for recurrent reactions that are similar in severity [<a href="#rid45">45-47</a>]. Other diagnostic tests, including noncontrast CT, ultrasound, or MRI should be pursued. </p><p></p><p class="bulletIndent1">However, if the clinical scenario requires that contrast be given (this situation should be rare; eg, CT angiography for suspected aortic injury when MRI is not feasible), the exam should be performed with the following precautions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Setting </strong>– Performance in a setting with expertise (ie, code team) and equipment for advanced cardiopulmonary resuscitation on standby, because changing the contrast agent and administering premedication do not eliminate the risk of a repeat reaction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Premedication </strong>– Premedication that includes at least two doses of corticosteroids plus antihistamines (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>). (See <a class="local">'Premedication regimens'</a> below.) </p><p></p><p class="bulletIndent2">If the urgency of the examination prevents administration of the full course of premedication, an abbreviated regimen should be given, as time allows, taking into account the risks and benefits of making the diagnosis and risk of repeat reaction (final row of the table) (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><strong>Other interventions:</strong> There are two additional interventions to prevent recurrence of allergic-like reactions that may be appropriate in some settings. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Change agent </strong>– Retrospective reviews have found that use of a contrast agent that is different from the one that caused the past reaction may also lower the incidence of recurrent allergic-like reactions, including changing from one LOCM to another [<a href="#rid46">46-48</a>]. The data are reviewed below. (See <a class="local">'Change of contrast agent'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Referral to an allergist </strong>– If there is sufficient time and access to an allergist familiar with emerging literature, the patient can be referred for skin testing with a panel of contrast agents to identify specific agents that are safer alternatives for that individual. In the past, when HOCM was routinely used, severe contrast reactions were almost never IgE-mediated and skin testing was not useful. However, now that LOCM is standard, severe allergic-like reactions are even more rare, but there is mounting evidence that some are IgE-mediated. Note that studies in support of skin testing are relatively new, and familiarity with this approach is not widespread, so communication between the radiologist and allergist to see if testing is available is essential. The optimal time period in which to perform skin testing appears to be within two to six months of the index reaction, although testing after this time period can still be informative. The allergy evaluation is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">"Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"</a>.)</p><p></p><p class="bulletIndent1">Note that test doses (or test injections) are <strong>not</strong> recommended for identifying patients at risk for repeat allergic-like reactions, because they do not predict tolerance of a full dose of contrast and can induce a repeat severe reaction in susceptible patients [<a href="#rid41">41,49,50</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate or mild allergic-like</strong> – If contrast is deemed necessary, the CT exam should be preceded by corticosteroid/antihistamine prophylaxis and should be performed in a setting with the expertise to treat a recurrent reaction readily available (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>). If the urgency of the examination prevents administration of the full course of premedication, an abbreviated regimen should be given, as time allows, taking into account the risks and benefits of making the diagnosis and risk of repeat reaction (final row of the table) (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>). In patients who are premedicated for a prior mild allergic-like contrast reaction, the likelihood of a severe breakthrough reaction is low (&lt;1 percent) [<a href="#rid46">46</a>]. Similar to the prevention of severe reactions, using a contrast agent that is different from the one that caused the past reaction may also lower the risk of a recurrence. (See <a class="local">'Change of contrast agent'</a> below.)</p><p></p><p class="headingAnchor" id="H2769960299"><span class="h4">Premedication regimens</span><span class="headingEndMark"> — </span>Standard premedication regimens are usually administered orally, beginning 12 to 13 hours before the examination, or intravenously administered beginning five hours before. If an urgent examination requires contrast and there is insufficient time for premedication, the exam indication and the risks and benefits of contrast administration should be discussed with a radiologist. In general, if the prior reaction was mild, an emergency and necessary CT exam requiring contrast should <strong>not</strong> be delayed for premedication.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – Use of premedication varies considerably with each practice, as it is unclear whether it is helpful in preventing moderate and severe reactions. Regimens containing two or more doses of corticosteroid beginning 12 or 13 hours before the procedure are better supported by evidence than regimens consisting of a single dose given closer to the procedure. The inclusion of <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> has not been specifically studied and can be considered optional, although antihistamines are commonly included [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">For elective CT in outpatients, premedication is given orally using one of the following two regimens (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimen 1</strong>: Three doses of 50 mg oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> administered 13, 7, and 1 hour prior to contrast administration, plus 50 mg oral <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> administered 1 hour prior to contrast administration [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimen 2</strong>: Two doses of 32 mg oral <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> administered 12 and 2 hours prior to contrast material administration, plus 50 mg oral <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> administered 1 hour prior to contrast administration [<a href="#rid53">53,54</a>]. </p><p></p><p class="bulletIndent1">The choice between these two regimens is determined by local radiology and institutional practice. Oral regimens shorter than 12 hours have not been shown to be effective; a two-hour oral regimen was shown to be no more effective than placebo [<a href="#rid1">1,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous</strong> – For patients in the emergency department or admitted to the hospital, shorter, 5-hour intravenous regimens are preferred and are not inferior to a 13-hour oral regimen (breakthrough reaction rates of 2.5 versus 2.1 percent) (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>) [<a href="#rid55">55</a>]. In contrast, intravenous regimens shorter than four to five hours have not been shown to be effective [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Option 1:</strong> Two doses of 200 mg intravenous <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> administered 5 and 1 hour prior to contrast material administration, plus 50 mg intravenous <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> administered 1 hour prior to contrast material administration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Option 2:</strong> Two doses of 40 mg intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> administered 5 and 1 hour prior to contrast material administration, plus 50 mg intravenous <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> administered 1 hour prior to contrast material administration.</p><p></p><p class="headingAnchor" id="H1136070498"><span class="h5">Efficacy and adverse effects</span><span class="headingEndMark"> — </span>Although premedication decreases the likelihood of recurrent allergic-like reactions, it does not prevent them altogether [<a href="#rid47">47</a>]. Breakthrough reactions occur in approximately 2 percent of patients [<a href="#rid45">45,46</a>]. In patients with prior breakthrough reactions, the likelihood of a subsequent breakthrough reaction is higher, at approximately 10 percent [<a href="#rid46">46</a>].</p><p>The best evidence supporting premedication was with HOCM, where the associated rates of acute reaction were high. With LOCM, now used universally in part because of its much lower rates of acute reactions, the benefit is less clear. Premedication decreases the likelihood of a mild reaction, but its efficacy in preventing moderate and severe reactions has not been proven [<a href="#rid33">33-35,37,39-41,45,46,51,52,54,56-60</a>]. </p><p>A randomized trial in the general population showed that premedication prior to LOCM administration reduced the likelihood of all immediate adverse events from 4.9 percent to 1.7 percent [<a href="#rid54">54</a>]. This trial was not sufficiently powered to evaluate the efficacy of premedication in the prevention of moderate or severe reactions. </p><p>The incidence of a recurrent allergic-like reaction in high-risk nonpremedicated patients is estimated to range from 10 to 35 percent [<a href="#rid33">33,41,46</a>]. With premedication, the risk is estimated to be approximately 10 percent [<a href="#rid45">45,46</a>]. </p><p>Due to the small effect of premedication and the rarity of contrast reactions in general, the number needed to treat to prevent one reaction is large. The estimated number needed to premedicate with a 13-hour oral regimen to prevent one allergic-like contrast reaction is 69 for any severity of reaction, 569 to prevent a severe reaction, and greater than 50,000 to prevent a death [<a href="#rid57">57,59,60</a>]. </p><p>The direct adverse effects of premedication are minor [<a href="#rid53">53,54</a>]. Transient leukocytosis and asymptomatic hyperglycemia have been observed. <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">Diphenhydramine</a> may cause drowsiness and should not be taken shortly before operating a vehicle.</p><p>The delay imparted by a 12- or 13-hour premedication regimen can expose hospitalized patients to indirect risks. One study of an inpatient population showed that a 13-hour oral premedication protocol was associated with a median 25-hour delay in time-to-CT and prolongation in length of stay, as well as an increased risk of nosocomial infection. For these reasons, a shorter five-hour intravenous regimen is preferred for inpatients [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H2073771821"><span class="h4">Change of contrast agent</span><span class="headingEndMark"> — </span>A small number of retrospective studies have suggested that changing contrast agents can help to reduce the risk of recurrent allergic-like reactions [<a href="#rid47">47,48</a>]. In the largest, 771 cases in which the patients had a previous adverse reaction to contrast underwent repeat radiologic procedures using either the same agent again or a different agent, with or without premedications (although only a subset received a regimen involving two doses of corticosteroid) [<a href="#rid48">48</a>]. In patients not receiving premedication, the rate of recurrent reactions was 28 percent when the same contrast was given, compared with 5.2 percent when the contrast was changed. The rate was 8 percent when the patient was changed from one LOCM to another.</p><p>A second study specifically examined 150 patients with a history of past moderate-to-severe hypersensitivity reactions to LOCM who were re-exposed during 328 subsequent radiologic exams to the same or different LOCM with various degrees of premedication [<a href="#rid47">47</a>]. The rates of recurrence were 19 and 24 percent in patients with moderate and severe past reactions, respectively. Recurrences occurred in 28 percent when the same LOCM was used, compared with 13 percent when the LOCM was changed.</p><p>Although the quality of this evidence is low, the conclusions are consistent with the widely-held belief among allergists that premedication, regardless of the regimen, does not absolutely prevent anaphylaxis in a susceptible patient who is re-exposed to the same drug. Thus, in patients with past severe allergic-like reactions or reactions with any features of anaphylaxis, it is logical to change the contrast agent, in addition to administering premedication. </p><p class="headingAnchor" id="H3543456750"><span class="h3">Preventing recurrent physiologic reactions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe physiologic reaction</strong> – Contrast should be avoided. Other diagnostic tests, including noncontrast CT, ultrasound, or MRI should be pursued. If the clinical scenario requires that contrast be given (this situation should be rare; eg, CT angiography for suspected aortic injury and MRI is not feasible), the exam should be performed with expertise for advanced cardiopulmonary resuscitation (ie, code team) on standby. Corticosteroid prophylaxis is not helpful or necessary if there is certainty that the prior reaction was physiologic and not allergic-like. If in doubt, consider it to have been allergic-like and administer premedication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild or moderate physiologic reaction</strong> – If contrast is deemed necessary, the patient should be advised that the symptoms of the previous reaction may recur and reassured that they are likely to be transient. Premedication prophylaxis is not necessary.</p><p></p><p class="headingAnchor" id="H960921189"><span class="h1">ASSESSING RISK FOR CONTRAST-INDUCED NEPHROPATHY</span><span class="headingEndMark"> — </span>Patients with severely impaired baseline kidney function (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>) and those with acute kidney injury may be at risk for contrast-induced nephropathy (CIN) following intravenous iodinated contrast administration. In patients with eGFR ≥30 mL/min/1.73 m<sup>2</sup>, intravenous iodinated contrast can be safely administered. Oral and rectal contrast are not known to have any effect on kidney function (<a class="graphic graphic_algorithm graphicRef113233" href="/z/d/graphic/113233.html" rel="external">algorithm 2</a>). </p><p>Whether intravenous contrast administered with CT is nephrotoxic is a topic of debate [<a href="#rid61">61-70</a>]. It has been associated with a transient increase in serum creatinine in patients with baseline eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, but not in patients with baseline eGFR ≥30 mL/min/1.73 m<sup>2</sup> [<a href="#rid71">71</a>]. A meta-analysis controlling for comorbidities found similar rates of dialysis and mortality following contrast-enhanced CT versus unenhanced CT, even in the subgroup of patients with chronic kidney disease [<a href="#rid72">72</a>]. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography"</a>.)</p><p class="headingAnchor" id="H1346442595"><span class="h2">Indications for screening kidney function</span><span class="headingEndMark"> — </span>Assessment of eGFR should be obtained prior to contrast-enhanced CT in patients whose kidney function may be impaired (<a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">calculator 1</a>). </p><p>In addition, all hospitalized patients should have eGFR assessed prior to contrast <strong>unless</strong> they are receiving chronic hemodialysis, have evolving acute kidney injury, or require urgent imaging for a life-threatening condition.</p><p>The clinical features that would warrant assessment of eGFR in outpatients vary somewhat with each practice but may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>History of kidney disease – Solitary or transplanted kidney, history of kidney surgery, tumor, or chronic kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension requiring chronic medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years (optional).</p><p></p><p>The eGFR is not useful prior to contrast-enhanced CT in these scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of a life-threatening condition (eg, severe trauma, suspected aortic dissection); contrast possibly would be given regardless of kidney function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anuric patient undergoing hemodialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evolving acute kidney injury; serum creatinine is a lagging indicator of kidney damage and is<strong><em> </em></strong>not reliable.</p><p></p><p>As a rule of thumb, calculating eGFR within 30 days for outpatients and two days for inpatients suffices. But temporal criteria for eGFR measurement vary with each practice and are modified by individual patient's clinical status.</p><p class="headingAnchor" id="H1717614449"><span class="h1">PATIENTS WITH IMPAIRED KIDNEY FUNCTION</span></p><p class="headingAnchor" id="H3356985914"><span class="h2">Patients with eGFR ≥30</span><span class="headingEndMark"> — </span>In patients with normal or mild to moderately impaired kidney function (ie, estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73 m<sup>2</sup>) and without acute kidney injury, no special precautions to prevent contrast-induced nephropathy (CIN) are required before contrast-enhanced CT. </p><p class="headingAnchor" id="H3456811689"><span class="h2">Patients with eGFR &lt;30</span><span class="headingEndMark"> — </span>Patients with acute kidney injury and patients with severely impaired kidney function (ie, eGFR &lt;30 mL/min/1.73 m<sup>2</sup> but who are not receiving chronic hemodialysis) may be at risk for CIN. Other diagnostic tests, including noncontrast CT, magnetic resonance imaging (MRI), or ultrasound should be considered. </p><p>If contrast is to be administered, intravenous volume expansion with isotonic fluids may be an effective option. Other commonly studied prophylactic measures, such as intravenous <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> infusion and n-acetyl cysteine, are not well-supported by the literature and are not indicated. This issue is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography", section on 'Prevention among high-risk patients'</a>.)</p><p>There is no standardized regimen for volume expansion. Typical regimens (using intravenously administered normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or Ringer's lactate) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography", section on 'Volume expansion'</a>.)</p><p>Evidence for using volume expansion prophylaxis is primarily derived from patients undergoing angiography [<a href="#rid73">73-75</a>]. Benefits of volume expansion in patients undergoing contrast-enhanced CT have not been shown [<a href="#rid76">76</a>]. </p><p>Oral volume expansion has not been rigorously tested.</p><p class="headingAnchor" id="H219182162"><span class="h2">Patients with acute kidney injury</span><span class="headingEndMark"> — </span>Patients with or suspected of having acute kidney injury (eg, due to sepsis, myocardial infarction, or a large-volume hemorrhage) should be assumed to have severely impaired kidney function and may be at risk for CIN. Assessment of eGFR is not useful in such patients. They should be managed similarly to those with severely impaired kidney function. (See <a class="local">'Patients with eGFR &lt;30'</a> above.)</p><p class="headingAnchor" id="H1216933381"><span class="h2">Patients receiving dialysis</span><span class="headingEndMark"> — </span>No precautionary measures are necessary prior to contrast-enhanced CT in anuric patients receiving chronic hemodialysis. Since the kidneys are already nonfunctional, there is no additional risk to the kidneys from iodinated contrast administration. In patients who are oliguric (ie, peritoneal dialysis, chronic hemodialysis but still making urine), or in patients who are receiving temporary dialysis for acute kidney injury, there is a theoretical but as yet undemonstrated risk of accelerating progression to anuria or permanent hemodialysis with intravenous iodinated contrast. These patients should be managed similarly to those with severely impaired kidney function. (See <a class="local">'Patients with eGFR &lt;30'</a> above.) </p><p class="headingAnchor" id="H625662511"><span class="h2">Patients who received contrast within preceding 24 hours</span><span class="headingEndMark"> — </span>Recent iodinated contrast administration is not a contraindication for contrast-enhanced CT, nor are prophylactic measures for CIN indicated in this setting in patients who otherwise would not be considered at risk for CIN.</p><p>No absolute maximum volume of intravascular iodinated contrast that can be administered safely within a given time period has been established. In patients with normal kidney function, the half-life of most modern CT contrast agents is approximately two hours and, after 20 hours, essentially all of a single dose of iodinated contrast is eliminated. </p><p>In patients receiving intravenous iodinated contrast, a dose-toxicity relationship for acute kidney injury has not been reported. A dose-toxicity relationship has been shown in patients undergoing coronary angiography, but that relationship may be confounded (eg, patient morbidity, catheter dwell-time in the suprarenal aorta, case complexity) [<a href="#rid77">77</a>]. </p><p>If multiple doses of intravascular iodinated contrast material must be administered within a 24-hour period, there is no reason to recheck eGFR prior to each dose. Even if a prior dose was nephrotoxic, it would not induce a change in eGFR for many hours.</p><p class="headingAnchor" id="H2610224160"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3957427048"><span class="h2">Children</span><span class="headingEndMark"> — </span>Intravenous contrast has the same benefits and uses in children as in adults. Contrast may be indicated for suspected nonaccidental trauma. Children have a lower rate of immediate hypersensitivity contrast reactions than adults [<a href="#rid78">78</a>]. The risk of contrast-induced nephropathy (CIN) in children is theoretically similar to that of adults but has not been formally tested. Contrast dose in children is weight-based and is determined by the radiologist. </p><p class="headingAnchor" id="H1628051367"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span>Iodinated contrast administered during pregnancy is not known to cause fetal harm. Neonatal hypothyroidism was a theoretical concern in the past but has been largely refuted by retrospective observational studies [<a href="#rid79">79,80</a>]. Intravenous contrast media crosses the placenta and enters the amniotic fluid and fetal circulation. Since the primary concern of potential harm to the fetus is exposure to ionizing radiation, the imaging protocol should err on the side of giving contrast if it may be helpful to avoid the need for repeat scanning.</p><p class="headingAnchor" id="H3009161019"><span class="h2">Breastfeeding women</span><span class="headingEndMark"> — </span>Infant ingestion of iodinated contrast excreted in breast milk is not known to be harmful. The amount that might be ingested and subsequently absorbed systemically is extremely small compared with clinically administered intravenous and oral doses [<a href="#rid81">81</a>]. If the mother wishes to not expose her infant even to any small amount of contrast, she may choose to discard her breast milk for 24 hours after she receives contrast material, but it is not medically necessary to do.</p><p class="headingAnchor" id="H1357077828"><span class="h2">Patients with allergies or asthma</span><span class="headingEndMark"> — </span>Patients with allergies to foods or medications appear to be at a modest (ie, two- to threefold) increased risk for allergic-like reactions to contrast, but avoidance of contrast or routine premedication for this reason is not recommended [<a href="#rid1">1</a>]. Note that seafood or shellfish allergies do not confer additional risk beyond that associated with having an allergy in general [<a href="#rid82">82,83</a>]. Similarly, patients with asthma are at some increased risk of an allergic-like contrast reaction, but neither avoidance of contrast nor routine premedication are indicated [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H1301967802"><span class="h2">Pheochromocytoma</span><span class="headingEndMark"> — </span>There is no increased risk of adrenergic crisis in patients with pheochromocytoma receiving modern intravenous iodinated contrast (ie, low-osmolality contrast media [LOCM], iso-osmolality contrast media [IOCM]) [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H3539982661"><span class="h2">Sickle-cell disease</span><span class="headingEndMark"> — </span>There is no increased risk of sickle crisis for patients with sickle cell disease receiving modern intravenous iodinated contrast (ie, LOCM, IOCM) [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H4180219542"><span class="h2">Patients taking metformin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> can increase the risk for lactic acidosis in patients with severe renal dysfunction (ie, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>) and is contraindicated in this setting. If the patient has normal or mildly impaired renal function (ie, eGFR ≥30 mL /min/1.73 m<sup>2</sup>), metformin need not be withheld before the CT examination, and the patient's renal function does not need to be followed after contrast administration.</p><p class="headingAnchor" id="H515430870"><span class="h2">Radioactive iodine imaging or therapy</span><span class="headingEndMark"> — </span>Iodinated contrast interferes with imaging or therapy that requires thyroid uptake of radioactive iodine. In patients undergoing or about to undergo procedures involving radioactive iodine, iodinated contrast administration should be deferred, if possible. If a contrast-enhanced CT is necessary, a washout period of four to eight weeks is needed before imaging or therapy with radioactive iodine [<a href="#rid86">86</a>]. Consult with a nuclear medicine clinician or radiologist for specific advice.</p><p class="headingAnchor" id="H3486487916"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate contrast utilization is necessary to obtain acceptable diagnostic accuracy. Omitting contrast when it is indicated, or giving it when it is not, can lead to diagnostic and treatment errors, and unnecessary morbidity and cost. Added or repeat tests, delayed diagnosis, and accumulated patient radiation exposure are all potential adverse effects of a suboptimal imaging exam. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute adverse reactions to contrast may occur after oral, intracavitary, or intravascular administration. For any history of an acute reaction to contrast, the provider should verify that the reaction was to an iodinated contrast (used for computed tomography [CT], radiography, fluoroscopy, or angiography) rather than to a noniodinated contrast agent used for other imaging modalities (eg, gadolinium used for magnetic resonance imaging [MRI]). The clinical details of the index reaction such as symptoms, their duration, and required therapy should also be obtained. (See <a class="local">'Patients with past reactions to contrast'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features of the previous immediate contrast reaction should be classified based on the severity (mild, moderate, or severe) and underlying physiology (allergic-like or physiologic). This classification predicts the likelihood and probable severity of a recurrent reaction and determines the need for premedication prophylaxis (<a class="graphic graphic_algorithm graphicRef113232" href="/z/d/graphic/113232.html" rel="external">algorithm 1</a>). (See <a class="local">'Clinical features of immediate reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of allergic-like reactions in patients with previous reactions depends on the severity of the index reaction because the majority of recurrent reactions are similar in severity to the index reaction:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a prior <strong>severe</strong> allergic-like reaction, the safest approach is future avoidance of contrast and use of alternate imaging modalities. However, if repeat administration of contrast is necessary, the CT should be performed in a setting with expertise (ie, code team) and equipment for advanced cardiopulmonary resuscitation on standby. In addition, we recommend administering premedication prophylaxis (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>), and we suggest using a contrast agent that is different from the one that caused the previous reaction (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with prior <strong>mild-to-moderate</strong> allergic-like reactions, we suggest that such patients receive premedication prophylaxis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, in patients with moderate past reactions, we suggest using a contrast agent that is different from the one that caused the previous reaction, if available (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1">Commonly used premedication regimens include at least two doses of corticosteroid plus an antihistamine (<a class="graphic graphic_table graphicRef59096" href="/z/d/graphic/59096.html" rel="external">table 1</a>). Standard premedication regimens are usually administered orally over 12 to 13 hours, or intravenously over five hours. If an urgent examination requires contrast and there is insufficient time for premedication, the exam indication and the risks and benefits of contrast administration should be discussed with a radiologist. In general, if the prior reaction was mild, an emergency and necessary CT exam requiring contrast should<strong> not</strong> be delayed for premedication. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1">Finally, there is recent and growing evidence that, in patients with severe past allergic-like reactions to low-osmolality contrast media (LOCM), referral to an allergist for skin testing can identify safer agents for that individual, but familiarity with this is not widespread among either radiologists or allergists. (See  <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">"Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severely impaired renal function (ie, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>) who are not anuric receiving chronic hemodialysis may be at risk for contrast-induced nephropathy (CIN). In addition, patients with or suspected of having acute kidney injury (eg, due to sepsis, myocardial infarction, or a large-volume hemorrhage) should be assumed to have severely impaired kidney function and may be at risk for CIN. In these patients, other diagnostic tests, including noncontrast CT, MRI, or ultrasound should be considered. If contrast is to be administered, intravenous volume expansion with isotonic fluids may be an effective option (<a class="graphic graphic_algorithm graphicRef113233" href="/z/d/graphic/113233.html" rel="external">algorithm 2</a>). (See <a class="local">'Patients with eGFR &lt;30'</a> above.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous iodinated contrast can be safely administered to patients who have stable eGFR ≥30 mL/min/1.73 m<sup>2</sup> and in those who are anuric on chronic hemodialysis. (See <a class="local">'Patients with eGFR ≥30'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, American College of Radiology 2020. https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/Contrast_Media.pdf (Accessed on September 24, 2020).</li><li><a class="nounderline abstract_t">Young BM, Fletcher JG, Booya F, et al. Head-to-head comparison of oral contrast agents for cross-sectional enterography: small bowel distention, timing, and side effects. J Comput Assist Tomogr 2008; 32:32.</a></li><li><a class="nounderline abstract_t">Megibow AJ, Babb JS, Hecht EM, et al. Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology 2006; 238:87.</a></li><li><a class="nounderline abstract_t">Davis JS, Ryan ML, Fields JM, et al. Use of CT enterography for the diagnosis of lower gastrointestinal bleeding in pediatric patients. J Pediatr Surg 2013; 48:681.</a></li><li class="breakAll">Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. AJNR Am J Neuroradiol 2013; 34:E117.</li><li><a class="nounderline abstract_t">Mullins ME. Emergent neuroimaging of intracranial infection/inflammation. Radiol Clin North Am 2011; 49:47.</a></li><li><a class="nounderline abstract_t">Hijaz TA, Cento EA, Walker MT. Imaging of head trauma. Radiol Clin North Am 2011; 49:81.</a></li><li><a class="nounderline abstract_t">Phuttharak W, Sawanyawisuth K, Kawiwungsanon A, Tiamkao S. The appropriate neuroimaging study in persons with epilepsy. Neurol Sci 2011; 32:969.</a></li><li class="breakAll">Groell R, Doerfler O, Schaffler GJ, Habermann W. Contrast-enhanced helical CT of the head and neck: improved conspicuity of squamous cell carcinoma on delayed scans. AJR Am J Roentgenol 2001; 176:1571.</li><li class="breakAll">Keberle M, Tschammler A, Hahn D. Single-bolus technique for spiral CT of laryngopharyngeal squamous cell carcinoma: Comparison of different contrast material volumes, flow rates, and start delays. Radiology 2002; 224:171.</li><li><a class="nounderline abstract_t">Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354:2317.</a></li><li><a class="nounderline abstract_t">Desjardins B, Kazerooni EA. ECG-gated cardiac CT. AJR Am J Roentgenol 2004; 182:993.</a></li><li><a class="nounderline abstract_t">Schroeder S, Achenbach S, Bengel F, et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J 2008; 29:531.</a></li><li><a class="nounderline abstract_t">American College of Cardiology Foundation Task Force on Expert Consensus Documents, Mark DB, Berman DS, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 55:2663.</a></li><li class="breakAll">ACR-STR practice parameter for the performance of high-resolution computed tomography (HRCT) of the lungs in adults. https://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/HRCT_Lungs.pdf (Accessed on May 14, 2017).</li><li><a class="nounderline abstract_t">Yamashita Y, Komohara Y, Takahashi M, et al. Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study. Radiology 2000; 216:718.</a></li><li><a class="nounderline abstract_t">Baker ME, Hara AK, Platt JF, et al. CT enterography for Crohn's disease: optimal technique and imaging issues. Abdom Imaging 2015; 40:938.</a></li><li><a class="nounderline abstract_t">Keyzer C, Cullus P, Tack D, et al. MDCT for suspected acute appendicitis in adults: impact of oral and IV contrast media at standard-dose and simulated low-dose techniques. AJR Am J Roentgenol 2009; 193:1272.</a></li><li><a class="nounderline abstract_t">Fayad LM, Bluemke DA, Fishman EK. Musculoskeletal imaging with computed tomography and magnetic resonance imaging: when is computed tomography the study of choice? Curr Probl Diagn Radiol 2005; 34:220.</a></li><li><a class="nounderline abstract_t">Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.</a></li><li><a class="nounderline abstract_t">Kumamaru KK, Hoppel BE, Mather RT, Rybicki FJ. CT angiography: current technology and clinical use. Radiol Clin North Am 2010; 48:213.</a></li><li><a class="nounderline abstract_t">Rubin GD, Leipsic J, Joseph Schoepf U, et al. CT angiography after 20 years: a transformation in cardiovascular disease characterization continues to advance. Radiology 2014; 271:633.</a></li><li><a class="nounderline abstract_t">Fuentes-Orrego JM, Pinho D, Kulkarni NM, et al. New and evolving concepts in CT for abdominal vascular imaging. Radiographics 2014; 34:1363.</a></li><li class="breakAll">Megibow AJ. Oral contrast utilization for abdominal/pelvic CT scanning in today’s emergency room setting. Abdom Radiol 2017; 42:781.</li><li><a class="nounderline abstract_t">Kielar AZ, Patlas MN, Katz DS. Oral contrast for CT in patients with acute non-traumatic abdominal and pelvic pain: what should be its current role? Emerg Radiol 2016; 23:477.</a></li><li><a class="nounderline abstract_t">Ramalingam V, Bates DD, Buch K, et al. Diagnosing acute appendicitis using a nonoral contrast CT protocol in patients with a BMI of less than 25. Emerg Radiol 2016; 23:455.</a></li><li><a class="nounderline abstract_t">Saadat L, Helenowski I, Mahvi D, Boller AM. Should Oral Contrast Be Omitted in Patients with Suspected Appendicitis? J Gastrointest Surg 2016; 20:1150.</a></li><li><a class="nounderline abstract_t">Reich SB. Production of pulmonary edema by aspiration of water-soluble nonabsorbable contrast media. Radiology 1969; 92:367.</a></li><li><a class="nounderline abstract_t">Boudiaf M, Soyer P, Terem C, et al. Ct evaluation of small bowel obstruction. Radiographics 2001; 21:613.</a></li><li class="breakAll">Vessal K, Montali RJ, Larson SM, et al. Evaluation of barium and gastrografin as contrast media for the diagnosis of esophageal ruptures or perforations. AJR Am J Roentgenol 1975; 123:307.</li><li><a class="nounderline abstract_t">Foley MJ, Ghahremani GG, Rogers LF. Reappraisal of contrast media used to detect upper gastrointestinal perforations: comparison of ionic water-soluble media with barium sulfate. Radiology 1982; 144:231.</a></li><li><a class="nounderline abstract_t">Swanson JO, Levine MS, Redfern RO, Rubesin SE. Usefulness of high-density barium for detection of leaks after esophagogastrectomy, total gastrectomy, and total laryngectomy. AJR Am J Roentgenol 2003; 181:415.</a></li><li><a class="nounderline abstract_t">Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621.</a></li><li><a class="nounderline abstract_t">Schabelman E, Witting M. The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed. J Emerg Med 2010; 39:701.</a></li><li><a class="nounderline abstract_t">Leung PS, Chen YC, Chu KH. Seafood allergy: tropomyosins and beyond. J Microbiol Immunol Infect 1999; 32:143.</a></li><li class="breakAll">ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, version 10.2. American College of Radiology website. https://www.acr.org/Quality-Safety/Resources/Contrast-Manual (Accessed on May 14, 2017).</li><li><a class="nounderline abstract_t">Wang CL, Cohan RH, Ellis JH, et al. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2008; 191:409.</a></li><li><a class="nounderline abstract_t">Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150.</a></li><li><a class="nounderline abstract_t">Christiansen C, Pichler WJ, Skotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000; 10:1965.</a></li><li><a class="nounderline abstract_t">Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol 2008; 190:666.</a></li><li><a class="nounderline abstract_t">Meth MJ, Maibach HI. Current understanding of contrast media reactions and implications for clinical management. Drug Saf 2006; 29:133.</a></li><li><a class="nounderline abstract_t">Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991; 157:1153.</a></li><li><a class="nounderline abstract_t">Almén T. The etiology of contrast medium reactions. Invest Radiol 1994; 29 Suppl 1:S37.</a></li><li><a class="nounderline abstract_t">Cohan RH, Dunnick NR. Intravascular contrast media: adverse reactions. AJR Am J Roentgenol 1987; 149:665.</a></li><li><a class="nounderline abstract_t">Freed KS, Leder RA, Alexander C, et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol 2001; 176:1389.</a></li><li><a class="nounderline abstract_t">Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009; 253:372.</a></li><li><a class="nounderline abstract_t">Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study. Eur Radiol 2017; 27:2886.</a></li><li><a class="nounderline abstract_t">Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to iodinated contrast medium: Premedication vs. changing the contrast medium. Eur Radiol 2016; 26:2148.</a></li><li><a class="nounderline abstract_t">Fischer HW, Doust VL. An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography. Radiology 1972; 103:497.</a></li><li><a class="nounderline abstract_t">Yamaguchi K, Katayama H, Takashima T, et al. Prediction of severe adverse reactions to ionic and nonionic contrast media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1991; 178:363.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R, Radin RC. Two pretreatment regimens for high-risk patients receiving radiographic contrast media. J Allergy Clin Immunol 1984; 74:540.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med 1985; 145:2197.</a></li><li><a class="nounderline abstract_t">Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317:845.</a></li><li><a class="nounderline abstract_t">Lasser EC, Berry CC, Mishkin MM, et al. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. AJR Am J Roentgenol 1994; 162:523.</a></li><li><a class="nounderline abstract_t">Mervak BM, Cohan RH, Ellis JH, et al. Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen. Radiology 2017; 285:425.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Halwig JM, Patterson R, Wallemark CB. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol 1986; 77:630.</a></li><li><a class="nounderline abstract_t">Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. AJR Am J Roentgenol 2015; 205:77.</a></li><li><a class="nounderline abstract_t">Loh S, Bagheri S, Katzberg RW, et al. Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement. Radiology 2010; 255:764.</a></li><li><a class="nounderline abstract_t">Davenport MS, Mervak BM, Ellis JH, et al. Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient Corticosteroid Prophylaxis before Contrast-enhanced CT. Radiology 2016; 279:492.</a></li><li><a class="nounderline abstract_t">Davenport MS, Cohan RH. The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients. Radiol Clin North Am 2017; 55:413.</a></li><li><a class="nounderline abstract_t">Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006; 239:392.</a></li><li><a class="nounderline abstract_t">Davenport MS, Khalatbari S, Dillman JR, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 2013; 267:94.</a></li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 2013; 267:119.</a></li><li><a class="nounderline abstract_t">Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010; 256:21.</a></li><li><a class="nounderline abstract_t">Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191:376.</a></li><li><a class="nounderline abstract_t">Katzberg RW, Barrett BJ. Risk of iodinated contrast material--induced nephropathy with intravenous administration. Radiology 2007; 243:622.</a></li><li class="breakAll">Hinson JS, Ehmann MR, Fine DM, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med 2017; 369:577.</li><li class="breakAll">McDonald JS, McDonald RJ, Williamson EE, et al. Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med 2017; doi: 10.1007/s00134-017-4699-y.</li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Carter RE, et al. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014; 271:65.</a></li><li><a class="nounderline abstract_t">Sinert R, Brandler E, Subramanian RA, Miller AC. Does the current definition of contrast-induced acute kidney injury reflect a true clinical entity? Acad Emerg Med 2012; 19:1261.</a></li><li><a class="nounderline abstract_t">Davenport MS, Khalatbari S, Cohan RH, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013; 268:719.</a></li><li><a class="nounderline abstract_t">McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 2013; 267:106.</a></li><li><a class="nounderline abstract_t">Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29.</a></li><li><a class="nounderline abstract_t">Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004; 62:1.</a></li><li><a class="nounderline abstract_t">Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998; 114:1570.</a></li><li><a class="nounderline abstract_t">Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389:1312.</a></li><li><a class="nounderline abstract_t">Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing contrast-induced nephropathy: where are we now? AJR Am J Roentgenol 2014; 202:784.</a></li><li><a class="nounderline abstract_t">Davenport MS, Dillman JR, Cohan RH, et al. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 2013; 266:773.</a></li><li><a class="nounderline abstract_t">Bourjeily G, Chalhoub M, Phornphutkul C, et al. Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero. Radiology 2010; 256:744.</a></li><li><a class="nounderline abstract_t">Atwell TD, Lteif AN, Brown DL, et al. Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients. AJR Am J Roentgenol 2008; 191:268.</a></li><li><a class="nounderline abstract_t">Nielsen ST, Matheson I, Rasmussen JN, et al. Excretion of iohexol and metrizoate in human breast milk. Acta Radiol 1987; 28:523.</a></li><li><a class="nounderline abstract_t">Beaty AD, Lieberman PL, Slavin RG. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med 2008; 121:158.e1.</a></li><li><a class="nounderline abstract_t">Boehm I. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med 2008; 121:e19.</a></li><li><a class="nounderline abstract_t">Mukherjee JJ, Peppercorn PD, Reznek RH, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 1997; 202:227.</a></li><li><a class="nounderline abstract_t">Morcos SK. Review article: Acute serious and fatal reactions to contrast media: our current understanding. Br J Radiol 2005; 78:686.</a></li><li><a class="nounderline abstract_t">Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012; 53:1633.</a></li></ol></div><div id="topicVersionRevision">Topic 113083 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/Contrast_Media.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, American College of Radiology 2020. https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/Contrast_Media.pdf (Accessed on September 24, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303285" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Head-to-head comparison of oral contrast agents for cross-sectional enterography: small bowel distention, timing, and side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16293806" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480934" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Use of CT enterography for the diagnosis of lower gastrointestinal bleeding in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480934" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Use of CT enterography for the diagnosis of lower gastrointestinal bleeding in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21111129" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Emergent neuroimaging of intracranial infection/inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21111131" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Imaging of head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21647630" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The appropriate neuroimaging study in persons with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21647630" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The appropriate neuroimaging study in persons with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21647630" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The appropriate neuroimaging study in persons with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738268" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multidetector computed tomography for acute pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15039178" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ECG-gated cardiac CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084017" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513611" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513611" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966700" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637126" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CT enterography for Crohn's disease: optimal technique and imaging issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843741" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : MDCT for suspected acute appendicitis in adults: impact of oral and IV contrast media at standard-dose and simulated low-dose techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269369" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Musculoskeletal imaging with computed tomography and magnetic resonance imaging: when is computed tomography the study of choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988217" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609871" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CT angiography: current technology and clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24848958" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CT angiography after 20 years: a transformation in cardiovascular disease characterization continues to advance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208285" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : New and evolving concepts in CT for abdominal vascular imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208285" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : New and evolving concepts in CT for abdominal vascular imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral contrast for CT in patients with acute non-traumatic abdominal and pelvic pain: what should be its current role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27392572" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosing acute appendicitis using a nonoral contrast CT protocol in patients with a BMI of less than 25.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925797" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Should Oral Contrast Be Omitted in Patients with Suspected Appendicitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5765945" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Production of pulmonary edema by aspiration of water-soluble nonabsorbable contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353110" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ct evaluation of small bowel obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353110" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ct evaluation of small bowel obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7089273" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reappraisal of contrast media used to detect upper gastrointestinal perforations: comparison of ionic water-soluble media with barium sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876019" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Usefulness of high-density barium for detection of leaks after esophagogastrectomy, total gastrectomy, and total laryngectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2343107" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20045605" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637712" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Seafood allergy: tropomyosins and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637712" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Seafood allergy: tropomyosins and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647910" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647034" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305580" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287437" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454540" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Current understanding of contrast media reactions and implications for clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1950858" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8071042" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The etiology of contrast medium reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307348" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravascular contrast media: adverse reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11373198" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789241" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Repeat contrast medium reactions in premedicated patients: frequency and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27975150" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26427700" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Protective effect against repeat adverse reactions to iodinated contrast medium: Premedication vs. changing the contrast medium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5022943" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1987594" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prediction of severe adverse reactions to ionic and nonionic contrast media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6491099" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Two pretreatment regimens for high-risk patients receiving radiographic contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2866755" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627208" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109489" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745940" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958391" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Emergency administration of radiocontrast media in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102383" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406882" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26536404" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient Corticosteroid Prophylaxis before Contrast-enhanced CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126223" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543592" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360737" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319662" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20574082" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647905" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446526" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of iodinated contrast material--induced nephropathy with intravenous administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446526" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk of iodinated contrast material--induced nephropathy with intravenous administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446526" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of iodinated contrast material--induced nephropathy with intravenous administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24475854" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23167857" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Does the current definition of contrast-induced acute kidney injury reflect a true clinical entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579046" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360742" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411756" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15267006" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872190" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233565" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24660707" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The challenges in assessing contrast-induced nephropathy: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238152" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634430" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18562757" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2960342" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Excretion of iohexol and metrizoate in human breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261505" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Seafood allergy and radiocontrast media: are physicians propagating a myth?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691465" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Seafood allergy and radiocontrast media: are physicians propagating a myth?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988215" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046418" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Review article: Acute serious and fatal reactions to contrast media: our current understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22787108" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
